RACE
Dear Health Care Professionals,
Gilead Sciences has always committed to drive innovation and improve patient lives and our ongoing focus is to advance viral hepatitis research, education and share best practices to achieve global elimination and cure. Undoubtedly, the RACE to beat viral hepatitis involves not only patients themselves, but the collaborative effort of the medical professionals, scientists, government and pharmaceutical industries. This monthly e-newsletter is a scientific platform for the Gilead Medical Affairs team to update you on recent advances and global innovative effort made to propel us to the next level. We hope it will spark up some interesting discussion among us.
Gilead Medical Affairs team
圖一、康復型 B 肝感染的腎移植受贈者 HBVr 與肝炎發作累積發生率
圖二、康復型 B 肝感染的腎移植受贈者 HBVr 累積發生率
表二、腎移植的 CHB 病人改用 TAF 治療的基線期特徵